What is the recommended STI (Sexually Transmitted Infection) prophylaxis regimen for a sexually active woman with a high-risk exposure?

STI Prophylaxis for Women

For women with high-risk sexual exposure, immediate empiric prophylaxis with ceftriaxone 500 mg IM plus doxycycline 100 mg orally twice daily for 7 days is recommended, along with metronidazole 2 g orally as a single dose if trichomoniasis risk is present. 1, 2

Immediate Post-Exposure Management (Within 72 Hours)

Empiric antimicrobial prophylaxis should be administered immediately without waiting for test results, as follow-up compliance is often poor and early treatment prevents complications like pelvic inflammatory disease (PID), ectopic pregnancy, and infertility. 1, 3

Recommended Prophylactic Regimen

• Ceftriaxone 500 mg IM single dose (covers gonorrhea; use 1 g if body weight >150 kg) 2, 3
• Doxycycline 100 mg orally twice daily for 7 days (covers chlamydia and early syphilis) 1, 2, 3
• Metronidazole 2 g orally single dose (covers trichomoniasis and bacterial vaginosis) 3, 2

Alternative to doxycycline if contraindicated: Azithromycin 1 g orally as a single dose, though doxycycline is now preferred based on superior efficacy data. 1, 2

Critical Timing Considerations

• Post-exposure prophylaxis must be initiated within 72 hours of exposure to be effective. 4, 3
• If this window has passed, prophylaxis is no longer indicated, but comprehensive screening remains essential. 3
• Doxycycline post-exposure prophylaxis (doxyPEP) at 200 mg within 72 hours is emerging as an effective strategy, though current evidence is strongest for men who have sex with men and transgender women, with ongoing trials in cisgender women. 5, 6

Comprehensive STI Screening Protocol

Even when prophylaxis is given, baseline and follow-up testing is mandatory because prophylaxis is not 100% effective and detects any infections already established at time of exposure. 3, 7

Immediate Baseline Testing (Day 0-3)

• Chlamydia and gonorrhea: Vaginal NAAT (preferred) or cervical specimen 1, 3, 7
• Syphilis: Both treponemal antibody test and RPR (reverse algorithm approach) 3, 8
• HIV: Fourth-generation antigen/antibody test 4, 3
• Trichomonas: Vaginal NAAT (not wet mount, which misses 30-40% of infections) 7, 8
• Hepatitis B surface antigen if unvaccinated 4, 3

Important: Nucleic acid amplification tests (NAATs) can detect chlamydia and gonorrhea even within 72 hours of exposure, making immediate testing valuable. 3

Follow-Up Testing Schedule

At 1-2 weeks post-exposure (if initial tests negative and no prophylaxis given):

• Repeat bacterial STI testing (chlamydia, gonorrhea, syphilis), as infectious agents may not have produced sufficient concentrations initially to be detected. 3

At 3 months post-exposure (mandatory for all patients):

• HIV testing (critical due to window period; laboratory-based Ag/Ab tests may miss early infection) 4, 3
• Syphilis serology (repeat if initial negative, as window period is 6-12 weeks) 3
• Reinfection screening for chlamydia/gonorrhea if initially positive and treated (reinfection rates 25-40%) 3, 7, 8

Vaccination

• Hepatitis B vaccination should be initiated immediately if the patient is unvaccinated, as HBV is frequently sexually transmitted. 4, 3
• Complete the full 3-dose series at 0,1-2 months, and 6 months. 3

Partner Management

All sexual partners within the preceding 60 days must be evaluated and treated, even if asymptomatic. 1, 3, 8

• Partners should receive the same empiric prophylactic regimen. 3
• Expedited partner therapy may be appropriate depending on local regulations. 3, 8
• Both patient and partners must abstain from sexual activity until 7 days after completing treatment to prevent reinfection. 1, 3

Risk Reduction Counseling

• Consistent and correct condom use for all future sexual encounters (new condom for each act, water-based lubricants only, hold base during withdrawal) 9, 10, 11
• Condoms reduce risk of HIV transmission by approximately 80-95% when used consistently and correctly, and provide significant protection against chlamydia, gonorrhea, syphilis, and trichomoniasis. 9, 11
• Both partners should be tested before initiating sexual activity with new partners. 3
• Limiting number of sexual partners and avoiding sex with persons from high-risk groups reduces STI exposure. 10

Special Populations and Considerations

Pregnancy Considerations

• Do not prescribe doxycycline to pregnant or breastfeeding women. 4
• Use azithromycin 1 g orally as alternative for chlamydia coverage. 1
• For pregnant women, safety data for tenofovir/emtricitabine (TDF/FTC) during pregnancy is incomplete, though no adverse effects have been found in infants exposed during pregnancy. 4

HIV-Infected Women

• HIV-infected women should receive the same treatment regimen as HIV-negative women. 1
• Treatment of cervicitis in HIV-infected women is vital because it reduces cervical HIV shedding and may reduce HIV transmission to partners. 1

Ongoing High-Risk Behavior

For women with continued high-risk behaviors (multiple or anonymous partners, sex work, substance use during sex, previous STI history), screening every 3-6 months is recommended indefinitely, not just after single exposures. 3, 7, 8

Common Pitfalls to Avoid

• Don't wait for test results before initiating prophylaxis in high-risk exposures—empiric treatment prevents complications and addresses poor follow-up compliance. 3
• Don't skip the 3-month follow-up testing—this is when HIV and syphilis become detectable if infection occurred. 3
• Don't rely on patient self-report of "always using condoms" as sufficient reassurance—condom effectiveness varies with actual versus reported use and correct versus incorrect use. 3
• Don't assume prophylaxis eliminates need for testing—prophylaxis is not 100% effective and may not cover all potential pathogens. 3
• Don't forget to treat partners—failure to treat partners leads to reinfection rates of 25-40%. 3, 7, 8